ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation - Clinical Trial NCTNCT05059444

Business Opportunities for NCT05059444

Connect with principal investigators, study coordinators, and key decision makers for this clinical trial studying investigational therapy for Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma.

Clinical Trial Information

Study Sponsor

Sponsor information available

Drug/Intervention

Study intervention details available

Therapeutic Area

Carcinoma, Adenocarcinoma, Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Carcinoma, Ovarian Epithelial, Esophageal Neoplasms, Urinary Bladder Neoplasms, Neoplasm, Residual

Study Phase

Phase information available

Study Status

RECRUITING

NCT Number

NCTNCT05059444

Find Contact Information

Access exclusive contact details for:

• Principal investigators and sub-investigators
• Study coordinators and research staff
• Site directors and facility contacts
• Sponsor representatives and CRO partners
• Business development professionals
• Clinical operations managers

Clinical Trial Locations

This study has 57 locations across United States, France, Germany, Italy, Spain.

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships